United Therapeutics Corp

UTHR

$170.11

+109.45% (1 year change)

Avg closing price

Price range

Market Cap

$9.05 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$380 Million

Total revenue in the last quarter.

Net Income

$171 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$11.54

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

17.59x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$221 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

920

The number of full time employees.

Revenue & Earnings

Balance Sheet

United Therapeutics Corp

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

News

United Therapeutics (UTHR) to Release Quarterly Earnings on Wednesday

United Therapeutics (UTHR) to Release Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is set to announce its earnings results before the market opens on Wednesday, February 24th. Analysts expect the company to announce earnings of $2.96 per share fo...

Transcript Daily Transcript Daily, 2 months ago
Alembic Global Holding SA gets USFDA nod for pulmonary arterial hypertension treatment injection

Alembic Global Holding SA gets USFDA nod for pulmonary arterial hypertension treatment injection

Drug firm Alembic Pharmaceuticals on Friday said its arm, Alembic Global Holding SA, has received approval from the US health regulator for its generic Treprostinil injection used for the treatment...

Economic Times India Economic Times India, 2 months ago
Hydrosurgery Systems Market Report Examines Unique Top Company Analysis by 2029 | United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Bayer AG and Pfizer Inc

Hydrosurgery Systems Market Report Examines Unique Top Company Analysis by 2029 | United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Bayer AG and Pfizer Inc

Hydrosurgery systems are seamlessly scaling up as a highly preferred treatment protocol over conventional wound debridement methods. In particular, handheld hydrosurgery systems are easier and safe...

OpenPR OpenPR, 3 months ago